Skip to search formSkip to main contentSkip to account menu

GMI-1070

Known as: Pan-Selectin Antagonist GMI-1070 
A synthetic, glycomimetic molecule and pan-selectin antagonist, with potential use in a vaso-occlusive crisis. Upon administration, GMI-1070 prevents… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Glycolipids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Emerging pharmacotherapeutic approaches for the management of sickle cell disease
ABSTRACT Introduction: Sickle cell disease (SCD) is an inherited disease with lifelong morbidity, whose complications include… 
2014
2014
Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis
Introduction: The pan-selectin antagonist rivipansel (GMI-1070) reduced intravascular arrest of red/white blood cell aggregates… 
Review
2012
Review
2012
Heparin mimetics.
Explorations of the therapeutic potential of heparin mimetics, anionic compounds that are analogues of glycosaminoglycans (GAGs… 
Review
2012
Review
2012
E-Selectin Ligands as Mechanosensitive Receptors on Neutrophils in Health and Disease
Application of mechanical force to bonds between selectins and their ligands is a requirement for these adhesion receptors to… 
2011
2011
Inhibition of E-Selectin Inflammatory Function by the Glycomimetic GMI-1070
Abstract 851 Introduction: E-selectin expression by endothelium plays dual roles in inflammation by supporting slow rolling and… 
2010
2010
GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease
Abstract 1632 GMI-1070 is a pan-selectin inhibitor that targets E-, P-, and L-selectins and has shown activity in multiple animal… 
2010
2010
Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion In Sickle Cell Disease: Results From a Phase 1/2 Study
Abstract 262 Adhesion molecules are critically involved in the pathophysiology of sickle cell disease (SCD). A growing body of… 
Review
2009
Review
2009
Safety, Tolerability and Pharmacokinetics of GMI-1070, a Pan-Selectin Inhibitor for Treatment of Vaso-Occlusive Crisis: Single and Multiple Dose Studies in Healthy Volunteers.
Abstract 1526 Poster Board I-549 Introduction GMI-1070 is a pan-selectin inhibitor which targets E-, P-, and L-selectin, and has… 
2008
2008
Effects of Pan-Selectin Antagonist GMI-1070 on the Treatment of Vaso-Occlusion in Sickle Cell Mice
Acute vaso-occlusion (VOC) in patients with sickle cell disease (SCD) induces intense pain arising from organ damage and is the… 
2007
2007
GMI-1070: A Small Pan-Selectin Antagonist That Inhibits Leukocyte Adhesion and Migration in Multple Disease Models In Vivo.
Rational design of glycomimetic inhibitors based on the bioactive conformation of functional carbohydrates provides new… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)